HUP0400775A2 - Specific human antibodies for selective cancer therapy - Google Patents

Specific human antibodies for selective cancer therapy

Info

Publication number
HUP0400775A2
HUP0400775A2 HU0400775A HUP0400775A HUP0400775A2 HU P0400775 A2 HUP0400775 A2 HU P0400775A2 HU 0400775 A HU0400775 A HU 0400775A HU P0400775 A HUP0400775 A HU P0400775A HU P0400775 A2 HUP0400775 A2 HU P0400775A2
Authority
HU
Hungary
Prior art keywords
human antibodies
cancer therapy
specific human
selective cancer
selective
Prior art date
Application number
HU0400775A
Other languages
English (en)
Hungarian (hu)
Inventor
Yocheved Hagai
Janette Lazarovits
Rachel Guy
Orly Lipschitz
Ester Szanthon
Avigdor Levanon
Daniel Plaksin
Tuvia Peretz
Original Assignee
Bio Technology General Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Technology General Corp filed Critical Bio Technology General Corp
Publication of HUP0400775A2 publication Critical patent/HUP0400775A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HU0400775A 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy HUP0400775A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75118100A 2000-12-29 2000-12-29
PCT/US2001/049440 WO2002059264A2 (en) 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy

Publications (1)

Publication Number Publication Date
HUP0400775A2 true HUP0400775A2 (en) 2007-05-02

Family

ID=25020844

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400775A HUP0400775A2 (en) 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy

Country Status (15)

Country Link
EP (1) EP1353937A4 (pt)
JP (1) JP2004524023A (pt)
KR (1) KR20030091952A (pt)
CN (1) CN100374456C (pt)
AU (1) AU2002246737B2 (pt)
BR (1) BR0116763A (pt)
CA (1) CA2433227A1 (pt)
CZ (1) CZ20031983A3 (pt)
HU (1) HUP0400775A2 (pt)
IL (1) IL156690A0 (pt)
MX (1) MXPA03005944A (pt)
NZ (1) NZ527173A (pt)
PL (1) PL365758A1 (pt)
RU (1) RU2316564C2 (pt)
WO (1) WO2002059264A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL374431A1 (en) * 2002-07-01 2005-10-17 Savient Pharmaceuticals, Inc. Compositions and methods for therapeutic treatment
CA2531283A1 (en) * 2003-06-30 2005-01-20 Bio-Technology General (Israel) Ltd. Specific human antibodies
AU2006238930B2 (en) 2005-04-26 2010-12-23 Pfizer Inc. P-cadherin antibodies
CA2747154C (en) * 2008-12-19 2015-11-10 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
CN110437320B (zh) * 2010-07-09 2023-10-20 阿菲博迪公司 多肽
CN101948534B (zh) * 2010-08-19 2014-05-28 中国科学院生物物理研究所 一种筛选抗体的方法
GB201310544D0 (en) * 2013-06-13 2013-07-31 Ucb Pharma Sa Obtaining an improved therapeutic ligand
BR122020006914B8 (pt) * 2014-10-23 2023-01-31 Singh Biotechnology Llc Anticorpo de domínio único anti-tnf-alfa e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
SG11201704726VA (en) * 2014-12-17 2017-07-28 Intrexon Corp Intercalated single-chain variable fragments
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
CN108290940B (zh) * 2015-10-01 2021-12-07 圣拉斐尔医院有限公司 Tcr及其用途
AU2016358296B2 (en) * 2015-11-19 2020-05-21 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
CN109843325B (zh) * 2016-09-14 2023-10-03 特尼奥生物股份有限公司 Cd3结合抗体
AU2021377688A1 (en) * 2020-11-13 2023-06-29 Cedars-Sinai Medical Center Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140470A (en) * 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies
CA2278106C (en) * 1997-01-22 2005-04-12 Board Of Regents, The University Of Texas System Tissue factor methods and compositions for coagulation and tumor treatment

Also Published As

Publication number Publication date
MXPA03005944A (es) 2005-04-29
WO2002059264A2 (en) 2002-08-01
RU2003123100A (ru) 2005-03-10
CN1551886A (zh) 2004-12-01
AU2002246737B2 (en) 2007-03-01
CN100374456C (zh) 2008-03-12
WO2002059264A3 (en) 2003-03-06
CZ20031983A3 (cs) 2005-07-13
EP1353937A4 (en) 2005-04-13
CA2433227A1 (en) 2002-08-01
KR20030091952A (ko) 2003-12-03
IL156690A0 (en) 2004-01-04
RU2316564C2 (ru) 2008-02-10
BR0116763A (pt) 2004-03-09
NZ527173A (en) 2006-03-31
PL365758A1 (en) 2005-01-10
EP1353937A2 (en) 2003-10-22
JP2004524023A (ja) 2004-08-12

Similar Documents

Publication Publication Date Title
EP1311262A4 (en) COMBINED TREATMENT AGAINST CANCER
GB2386120B (en) Differentiated cells suitable for human therapy
EP1572131A4 (en) ANTIBODY THERAPY
GB0028429D0 (en) Therapy
EP1296699A4 (en) THERAPEUTIC AGENTS - III
IL214262A0 (en) Therapeutic human anti-il-1r1 monoclonal antibody
AU2001251348A1 (en) Apparatus for sensing human prostate tumor
HUP0400775A2 (en) Specific human antibodies for selective cancer therapy
HUP0300005A3 (en) Modified cytokines for use in cancer therapy
GB2367993B (en) Radiotherapy apparatus
EP1178829A4 (en) HUMAN MONOCLONAL ANTIBODY
AU2002351374A8 (en) Antibodies to treat cancer
GB0001710D0 (en) Therapeutic treatment
GB0005257D0 (en) Breast cancer hormonal therapy
EP1401494A4 (en) TUMOR THERAPY
AU144325S (en) Therapy device
AU2096002A (en) Therapeutic treatment
GB0026015D0 (en) Cancer treatment
GB2374018B (en) Ultrasound therapy
GB0022216D0 (en) Human FAP-a-specific antibodies for use in cancer therapy
EP1463511A4 (en) COMBINATORY ANTICANCER THERAPY
SI1157041T1 (sl) Protitelesa za terapijo in diagnozo raka
GB0024673D0 (en) Therapeutic antibodies
GB9914057D0 (en) Antibody therapy
GB9927698D0 (en) Therapeutic antibody

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees